Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 17, 2007 Brian Orelli	FDA's Rigor May Boost Sales The FDA is updating labeling of certain blood-thinning drugs, indicating that patients may want to obtain a genetic test prior to taking the medication. This move may lead to increased testing, and hopefully increased prescriptions.
The Motley Fool August 29, 2011 Brian Orelli	Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive.
The Motley Fool February 4, 2010 Brian Orelli	Surfing the Wave of the Future: Personalized Medicine Medco buys in to personalized medicine. Yesterday Medco Health Solutions said it's purchasing genetic-testing expert DNA Direct.
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.
Chemistry World July 2010 Anna Lewcock	Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition.
BusinessWeek January 21, 2010 John Carey	Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
BusinessWeek September 5, 2005 Capell & Arndt	Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx.
Fast Company David Lumb	Sites That Sell Cancer Gene Tests Don't Tell Customers The Whole Story, Study Finds Consumer tests that analyze DNA from tumors in order to help personalize a patient's treatment are in something of a Wild West period.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool September 28, 2007 Brian Orelli	Side Effects No Match for This Tag Team Seven large drugmakers have come together to try and find genetic variations that cause medications to have serious side effects in some patients, but not in others.
Pharmaceutical Executive September 1, 2010	The Testing of the Tests FDA seeks to regulate genetic tests more actively, while encouraging diagnostic development.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
BusinessWeek September 5, 2005	Putting the FDA Out Front Deputy Commissioner Dr. Janet Woodcock explains how the agency has led the drive for personalized medicine.
Chemistry World February 25, 2015 Rebecca Trager	US opens up home DNA screening The US Food and Drug Administration has, for the first time, authorized a genetic test to be sold directly to consumers. The agency plans to ease the regulatory path for similar screening tests.
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool August 24, 2007 Brian Orelli	Take Your Medicine; Earn Your Profits Personalized medicine offers investment ideas. Let's take a look at what this new catchphrase in the medical community actually means, and how investors can benefit from it.
Fast Company Elizabeth Segran	23andMe And The FDA Reached A Pivotal Genetic Testing Agreement An FDA decision summary allows DNA-testing company 23andMe to market a genome test that screens for Bloom syndrome, a rare disorder that may lead toward the development of cancer.
Fast Company David Lumb	The FDA Just OK'd 23AndMe To Test For One Syndrome The FDA just gave consumer genetics testing company 23AndMe permission to sell tests for Bloom syndrome -- a disease associated with shortened height and an increased cancer risk.
Chemistry World June 22, 2011 Sarah Houlton	US Approves Cancer Drugs Twice as Fast as Europe Cancer drugs are, on average, approved nearly twice as fast in the US than they are in Europe.
The Motley Fool March 15, 2010 Brian Orelli	Warning: Not All Boxed Warnings Are Equal Plavix's is mild in comparison.
Pharmaceutical Executive December 1, 2013	FDA Pursues Delicate Balancing Act The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.
Bio-IT World December 15, 2003 Kevin Davies	The Road to Personalized Medicine FDA guidance on the road to genomic medicine is a welcome first step in what promises to be a contentious debate on how to integrate pharmacogenomics into routine medical practice.
The Motley Fool June 14, 2010 Bruce Bigelow	Genetic Testing Companies in San Diego, Boston, and San Francisco Studying FDA Letters The letters notify the companies that genome-sequencing tests they offer to consumers are medical devices that require the agency's approval.
American Journal of Nursing October 2009	Pharmacogenomics: Personalizing Drug Therapy Pharmacogenomics is a rapidly growing field of research into the ways in which genetic variation affects drug response.
The Motley Fool March 31, 2010 Brian Orelli	When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies.
Pharmaceutical Executive July 1, 2011 Dickmeyer & Rosenbeck	From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition?
The Motley Fool May 28, 2010 Brian Orelli	Is It Time to Make Money Investing in Genetic Testing? Easier said than done.
Chemistry World February 22, 2011 Amaya Camara-Campos	Repairing faulty genes Israeli scientists have developed compounds that could be better treatments for genetic diseases than current drugs.
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
The Motley Fool February 23, 2010 Brian Orelli	Triple-Teaming Cancer for Fun and Profit Pfizer, Merck and Eli Lilly set up a nonprofit, but there may be an ulterior motive.
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.
Managed Care May 2001 Michael D. Dalzell	Powerful Opportunities For Good and Greed Genetic advances could spawn incredible improvements in health care. Given public demand, they also pose what may be unmanageable issues of resource use...
HHMI Bulletin May 2012 Sarah C. P. Williams	Stephen Quake: Innovative Thinking on Genetic Tests His ideas have already led to a blood test to tell a pregnant woman whether her fetus has Down syndrome. Now, the HHMI investigator is pushing further, to track the success of heart transplants and diagnose autoimmune diseases and allergies.
Managed Care November 2006 Maureen Glabman	Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part.
Bio-IT World November 14, 2003 Kathy Ordonez	Targeted Medicine via Molecular Diagnostics Using diagnostics to select and deselect target populations for drug therapy will enable life scientists to make more effective medicines.
Pharmaceutical Executive March 1, 2012 Ron Cohen	FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership.
Bio-IT World August 13, 2003 John Rhodes	Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert.
American Journal of Nursing August 2010 Lomas & Fowler	Parents and Children with Cystic Fibrosis A survey was conducted to estimate how many adult patients with cystic fibrosis who receive care at centers accredited by the Cystic Fibrosis Foundation also have biological children with the disease.
Managed Care September 2002	Aetna Chief Wants Coverage For Genetic Tests The CEO of the country's largest for-profit HMO has jumped with both feet into the national discussion about genetic testing's place in health care.
Nurse Practitioner August 2009 Linda A. Howe	Pharmacogenomics and management of cardiovascular disease Prior to the completion of the Human Genome Project in 2003, individual responses to medications were usually termed idiosyncrasies. Ethnic differences were not usually seen as genetic variants, as is the case today.
Pharmaceutical Executive January 1, 2006 Kenneth I. Kaitin	Opinion: Memo to von Eschenbach FDA's acting commissioner has an opportunity to clarify a lot of misconceptions about the agency's role in regulating drug safety. His first order of business should be to explain exactly what FDA doesn't do.
Pharmaceutical Executive June 1, 2012 Jill Wechsler	Innovation and Collaboration A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market.
Pharmaceutical Executive June 1, 2007 Clinton & Wechsler	The View From Inside Commissioner Andrew von Eschenbach on drug safety, DTC advertising, FDA's culture, and how the agency plans to bring itself into the age of molecular medicine.
BusinessWeek November 7, 2005 Catherine Arnst	How Likely Are You To Get Sick? A new DNA database could gauge your risk for disease.
Chemistry World October 25, 2007 Arthur Rogers	European Ethical Guidelines Weigh in Against Mail Order Genetic Tests The Council of Europe (CoE) has come out against mail-order and over-the-counter genetic tests in new ethical guidelines that seek to address dilemmas faced by health services without hobbling scientific progress towards 'personalized medicine'.
Pharmaceutical Executive April 1, 2006 Jill Wechsler	Washington Report: A Warning Trend Washington's new answer to drug safety concerns is more warnings and more disclosure of undigested data. But warnings can go too far. Haven't FDA's critics ever heard the story of the boy who cried wolf?
Managed Care March 2005	Lawmakers Seek To Closely Watch Genetic Info Flow The U.S. Senate is looking to create a bill that states health coverage cannot be denied based on genetic information.
Managed Care May 2005 Martin Sipkoff	Predictive Modeling & Genomics: Marriage of Promise and Risk Integration of predictive modeling and genomic tools means improved technology, enhanced databases, and appropriate legal guidance.